Document is current

Article History

Received: 26 September 2022

Accepted: 22 June 2023

First Online: 3 July 2023

Declarations

:

: Lars Bendtsen (LB) and Sonja Antic (SA) have both served on the scientific advisory board for Novartis, AbbVie (Allergan), Teva, Lundbeck, and Eli Lilly. The work of Nikolaj Siersbæk (NS), Lærke Kilsdal (LK), and Christian Jervelund (CJ) was funded my Novartis (POP3 number DK2201120023). CJ is a Partner of Copenhagen Economics, who received funding from Novartis. Novartis was involved in the study’s initiation and decision to submit it for publication, but neither Novartis and the other companies cited above nor anyone other than the authors had any involvement in the study’s design, data collection, analysis and interpretation, or writing of the manuscript.

: All methods were carried out in accordance with the relevant guidelines and regulations. As this is a non-interventional study based on survey data that does not involve human biological material, ethical approval is not required from the Danish research ethics committee system according to Danish legislation (LBK nr 1338 af 01/09/2020) § 14, stk. 2 [Act no. 1338 of 1 September 2020, Sect. 14, subsection 2] [CitationRef removed]). Before initiating the survey for gathering RWD, the participants provided informed consent to participate in the survey. Data processing in the study was in accordance with the General Data Protection Regulation (nr 20/8964).

: Not applicable.

: NS, LK, and CJ are employees of Copenhagen Economics, which is one of the leading economics firms in Europe. Founded in 2000, we currently have more than 100 employees operating from our offices in Copenhagen, Stockholm, Helsinki, and Brussels. The Global Competition Review (GCR) lists Copenhagen Economics among the top 20 economic consultancies in the world, and has done so since 2006.